South & Central America Glioma Treatment Market Forecast to 2030 - Regional Analysis - by Disease, Treatment Type, Grade, and End User

List of Tables

The South & Central America glioma treatment market is expected to grow from US$ 117.14 million in 2022 to US$ 227.74 million by 2030. It is estimated to grow at a CAGR of 8.7% from 2022 to 2030.

Increasing Opportunities in Emerging Economies Fuels South & Central America Glioma Treatment Market

Brazil, Russia, India, China, and South Africa (BRICS) are among the fastest-growing economies in the world. The healthcare sectors in these countries, as well as other developing economies, are projected to expand rapidly in the coming years. The expected growth is ascribed to changes in customer demand, an increase in awareness about healthcare services, and a continuous rise in the aging population. The global brain cancer diagnostics market is likely to grow significantly in the coming years with the proliferation of the healthcare sector. Further, increased government spending on healthcare facilities and consumer purchasing power contribute to the growth of the healthcare sector in developing countries.

20 years before the COVID-19 epidemic, health service coverage in the Americas region improved, albeit slowly. Compared to 65% of people in 2000, 77% of people in 2019 had health insurance. Government spending on health expanded by 1.1 percentage points while the number of health personnel increased. Thus, the growing healthcare sector in the region creates opportunities for the glioma treatment market players to expand their business.

South & Central America Glioma Treatment Market Overview

The glioma treatment market in South & Central America is segmented into Brazil, Argentina, and the Rest of South & Central America. The market growth in this region is ascribed to the rising incidence of brain cancer and a spur in developments in healthcare systems. In addition, the universities in Latin American countries are collaborating with various private and public companies to support studies related to brain cancer treatment. The rising awareness about neurovascular disorders is also favoring the glioma treatment market in South & Central America.

Brazil is the fifth largest country in the world by area and population and is experiencing the fastest demographic aging as per the world data.info. As per the Globocan 2020 report, brain cancer is the most common cause of death in Brazil. 12,260 new cases of brain cancer were reported in Brazil in 2020, while brain and CNS cancers led to 10,920 deaths. Further, the 5-year prevalence rate of brain cancer in Brazil for all ages is ~15.17 per 100,000 population. The number of cancer cases in Argentina is increasing at a steady rate. According to the Globocan report published by the Global Cancer Observatory of the WHO, ~1,831 new cases of brain cancer were diagnosed in 2020, of which 1,488 deaths were reported due to brain cancer in Argentina. The 5-years prevalence rate of brain cancer for all age groups was found to be 11.62 per 100,000 population in Argentina.

Chile, Colombia, Peru, Cuba, Venezuela, and Bolivia are among other the key contributors to the glioma treatment market in South & Central America. These countries are improving their healthcare infrastructure by allowing new market players to enter into the marketplace. In addition, the countries in the Rest of South & Central America are investing and taking an interest in improving their healthcare research activities and adopting advanced therapies for brain cancer.

South & Central America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Million)

South & Central America Glioma Treatment Market Segmentation

The South & Central America glioma treatment market is segmented into disease, treatment type, grade, end user, and country.

Based on disease, the South & Central America glioma treatment market is segmented into astrocytoma, oligoastrocytoma, and oligodendroglioma. The astrocytoma segment held the largest share of the South & Central America glioma treatment market in 2022.

Based on treatment type, the South & Central America glioma treatment market is segmented into surgery, chemotherapy, radiation therapy, and others. The surgery segment held the largest share of the South & Central America glioma treatment market in 2022.

Based on grade, the South & Central America glioma treatment market is segmented into low grade and high grade. The high grade segment held a larger share of the South & Central America glioma treatment market in 2022.

Based on end user, the South & Central America glioma treatment market is segmented into hospital & clinics and ambulatory surgical center. The hospital & clinics segment held a larger share of the South & Central America glioma treatment market in 2022.

Based on country, the South & Central America glioma treatment market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the South & Central America glioma treatment market in 2022.

Amgen Inc, Biocon Ltd, F. Hoffmann-La Roche Ltd, Merck & Co Inc, Pfizer Inc, Sun Pharmaceutical Industries Ltd, and Teva Pharmaceutical Industries Ltd are some of the leading companies operating in the South & Central America glioma treatment market.

Product Code: BMIRE00029271

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. South & Central America Glioma Treatment Market - Key Industry Dynamics

4.1 Market Drivers
- 4.1.1 High Incidence Rate of Brain Cancer in South America
- 4.1.2 Increase in Prevalence of High-Grade Glioma
4.2 Key Market Restraints
- 4.2.1 High Cost of Diagnosis
4.3 Key Market Opportunities
- 4.3.1 Advancements in Healthcare Sector in Emerging Economies
4.4 Future Trends
- 4.4.1 Surge in Drug Approvals for Glioma Treatment
4.5 Impact Analysis:

5. Glioma Treatment Market - South & Central America Market Analysis

5.1 South & Central America Glioma Treatment Market Revenue (US$ Mn), 2022 - 2030

6. South & Central America Glioma Treatment Market - Revenue and Forecast to 2030 - by Disease

6.1 Overview
6.2 South & Central America Glioma Treatment Market Revenue Share, by Disease 2022 & 2030 (%)
6.3 Astrocytoma
- 6.3.1 Overview
- 6.3.2 Astrocytoma: South & Central America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Oligoastrocytoma
- 6.4.1 Overview
- 6.4.2 Oligoastrocytoma: South & Central America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
6.5 Oligodendroglioma
- 6.5.1 Overview
- 6.5.2 Oligodendroglioma: South & Central America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)

7. South & Central America Glioma Treatment Market - Revenue and Forecast to 2030 - by Treatment Type

7.1 Overview
7.2 South & Central America Glioma Treatment Market Revenue Share, by Treatment Type 2022 & 2030 (%)
7.3 Surgery
- 7.3.1 Overview
- 7.3.2 Surgery: South & Central America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Chemotherapy
- 7.4.1 Overview
- 7.4.2 Chemotherapy: South & Central America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
7.5 Radiation Therapy
- 7.5.1 Overview
- 7.5.2 Radiation Therapy: South & Central America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
7.6 Others
- 7.6.1 Overview
- 7.6.2 Others: South & Central America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)

8. South & Central America Glioma Treatment Market - Revenue and Forecast to 2030 - by Grade

8.1 Overview
8.2 South & Central America Glioma Treatment Market Revenue Share, by Grade 2022 & 2030 (%)
8.3 Low Grade
- 8.3.1 Overview
- 8.3.2 Low Grade: South & Central America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.1 Grade I: South & Central America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  - 8.3.2.2 Grade II: South & Central America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
8.4 High Grade
- 8.4.1 Overview
- 8.4.2 High Grade: South & Central America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  - 8.4.2.1 Grade III: South & Central America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
  - 8.4.2.2 Grade IV: South & Central America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)

9. South & Central America Glioma Treatment Market - Revenue and Forecast to 2030 - by End User

9.1 Overview
9.2 South & Central America Glioma Treatment Market Revenue Share, by End User 2022 & 2030 (%)
9.3 Hospital & Clinics
- 9.3.1 Overview
- 9.3.2 Hospital & Clinics: South & Central America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)
9.4 Ambulatory Surgical Centers
- 9.4.1 Overview
- 9.4.2 Ambulatory Surgical Centers: South & Central America Glioma Treatment Market - Revenue and Forecast to 2030 (US$ Million)

10. South & Central America Glioma Treatment Market - Country Analysis

10.1 South & Central America Glioma Treatment Market, Revenue and Forecast to 2030
- 10.1.1 Overview
  - 10.1.1.1 South & Central America Glioma Treatment Market, by Country
  - 10.1.1.2 Brazil
    - 10.1.1.2.1 Brazil: South & Central America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.1.1.2.2 Brazil: South & Central America Glioma Treatment Market, by Disease
    - 10.1.1.2.3 Brazil: South & Central America Glioma Treatment Market, by Treatment Type
    - 10.1.1.2.4 Brazil: South & Central America Glioma Treatment Market, by Grade
    - 10.1.1.2.4.1 Brazil: South & Central America Glioma Treatment Market, by Low Grade
    - 10.1.1.2.4.2 Brazil: South & Central America Glioma Treatment Market, by High Grade
    - 10.1.1.2.5 Brazil: South & Central America Glioma Treatment Market, by End User
  - 10.1.1.3 Argentina
    - 10.1.1.3.1 Argentina: South & Central America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.1.1.3.2 Argentina: South & Central America Glioma Treatment Market, by Disease
    - 10.1.1.3.3 Argentina: South & Central America Glioma Treatment Market, by Treatment Type
    - 10.1.1.3.4 Argentina: South & Central America Glioma Treatment Market, by Grade
    - 10.1.1.3.4.1 Argentina: South & Central America Glioma Treatment Market, by Low Grade
    - 10.1.1.3.4.2 Argentina: South & Central America Glioma Treatment Market, by High Grade
    - 10.1.1.3.5 Argentina: South & Central America Glioma Treatment Market, by End User
  - 10.1.1.4 Rest of South & Central America
    - 10.1.1.4.1 Rest of South & Central America: South & Central America Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
    - 10.1.1.4.2 Rest of South & Central America: South & Central America Glioma Treatment Market, by Disease
    - 10.1.1.4.3 Rest of South & Central America: South & Central America Glioma Treatment Market, by Treatment Type
    - 10.1.1.4.4 Rest of South & Central America: South & Central America Glioma Treatment Market, by Grade
    - 10.1.1.4.4.1 Rest of South & Central America: South & Central America Glioma Treatment Market, by Low Grade
    - 10.1.1.4.4.2 Rest of South & Central America: South & Central America Glioma Treatment Market, by High Grade
    - 10.1.1.4.5 Rest of South & Central America: South & Central America Glioma Treatment Market, by End User

11. Glioma Treatment Market Industry Landscape

11.1 Overview
11.2 Growth Strategies Done by the Companies in the Market, (%)
11.3 Organic Developments
- 11.3.1 Overview
11.4 Inorganic Developments
- 11.4.1 Overview

12. Company Profiles

12.1 F. Hoffmann-La Roche Ltd
- 12.1.1 Key Facts
- 12.1.2 Business Description
- 12.1.3 Products and Services
- 12.1.4 Financial Overview
- 12.1.5 SWOT Analysis
- 12.1.6 Key Developments
12.2 Merck & Co Inc
- 12.2.1 Key Facts
- 12.2.2 Business Description
- 12.2.3 Products and Services
- 12.2.4 Financial Overview
- 12.2.5 SWOT Analysis
- 12.2.6 Key Developments
12.3 Sun Pharmaceutical Industries Ltd
- 12.3.1 Key Facts
- 12.3.2 Business Description
- 12.3.3 Products and Services
- 12.3.4 Financial Overview
- 12.3.5 SWOT Analysis
- 12.3.6 Key Developments
12.4 Amgen Inc
- 12.4.1 Key Facts
- 12.4.2 Business Description
- 12.4.3 Products and Services
- 12.4.4 Financial Overview
- 12.4.5 SWOT Analysis
- 12.4.6 Key Developments
12.5 Teva Pharmaceutical Industries Ltd
- 12.5.1 Key Facts
- 12.5.2 Business Description
- 12.5.3 Products and Services
- 12.5.4 Financial Overview
- 12.5.5 SWOT Analysis
- 12.5.6 Key Developments
12.6 Pfizer Inc
- 12.6.1 Key Facts
- 12.6.2 Business Description
- 12.6.3 Products and Services
- 12.6.4 Financial Overview
- 12.6.5 SWOT Analysis
- 12.6.6 Key Developments
12.7 Biocon Ltd
- 12.7.1 Key Facts
- 12.7.2 Business Description
- 12.7.3 Products and Services
- 12.7.4 Financial Overview
- 12.7.5 SWOT Analysis
- 12.7.6 Key Developments

13. Appendix

13.1 About Us
13.2 Glossary of Terms